These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 15661407)

  • 1. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
    J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.
    Morales A; Black AM; Emerson LE
    BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Ebert T, Jockenhövel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late onset hypogonadism with transdermal testosterone gel. Eur Urol 2005;47:137-46.
    Ponholzer A; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):170-1; author reply 171. PubMed ID: 15967269
    [No Abstract]   [Full Text] [Related]  

  • 10. Testosterone supplementation: what and how to give.
    Jockenhövel F
    Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects.
    Schubert M; Jockenhövel F
    J Endocrinol Invest; 2005; 28(3 Suppl):23-7. PubMed ID: 16042356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
    Mulhall JP; Valenzuela R; Aviv N; Parker M
    Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal androgens: pharmacology and applicability to hypogonadal elderly men.
    Swerdloff RS; Wang C
    J Endocrinol Invest; 2005; 28(3 Suppl):112-6. PubMed ID: 16042369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
    Gould DC; Feneley MR; Kirby RS
    BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
    Morgunov LIu; Vertkin AL; Pushkar' DIu
    Urologiia; 2007; (5):49-51. PubMed ID: 18254226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer in men using testosterone supplementation.
    Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
    J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.